Lung Cancer Drug More Effective Than Chemotherapy

A new study shows encouraging results from the lung cancer drug erlotinib, indicating it can increase survival and improve quality of life in non-small-cell cancer patients.

Researchers studied the drug in 174 patients. Of the group, 55 percent responded to erlotinib, compared to 11 percent for chemotherapy. Patients lived without cancer progression for 9.4 months on average, compared to 5.2 months for those on chemotherapy. The drug is in in phase 3 of study, meaning it is in the last stage before being approved for public use.

Erlotinib, besides increasing survival rates, causes fewer negative side effects than chemotherapy. The lack of serious side effects also means it is less costly than treatments whose side effects are more debilitating. Read more…


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: